Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

@article{Zucchini2005FinalHI,
  title={Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.},
  author={Stefano Zucchini and Emanuela Scarano and Lilia Baldazzi and Laura Mazzanti and Piero Pirazzoli and Emanuele Cacciari},
  journal={Journal of endocrinological investigation},
  year={2005},
  volume={28 3},
  pages={
          274-9
        }
}
OBJECTIVE To report our experience on long-term treatment with recombinant-human-IGF-I (rhIGF-I) of a female patient with Laron syndrome (mutation G223G in the GH receptor gene), who received short-term treatment (1 yr) with LHRH analogue at the start of puberty and subsequently with oxandrolone. CASE REPORT The patient started IGF-I therapy (dose 40 microg/kg bid for 9 months, 80 microg/kg bid until 13.7 yr of age and 120 microg/kg bid thereafter) when she was 7.6 yr old (height -6 sds), and… CONTINUE READING
BETA

Topics from this paper.

Similar Papers

Loading similar papers…